# Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy

> **NCT00327223** · PHASE1 · COMPLETED · sponsor: **AmpliMed Corporation** · enrollment: 18 (actual)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **DRUG:** imexon

## Key facts

- **NCT ID:** NCT00327223
- **Lead sponsor:** AmpliMed Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-09
- **Final completion:** 2006-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2008-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327223, "Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00327223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*